

# Clinical trials of anacetrapib

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>anacetrapib vs placebo</b>			
<b>DEFINE , 2010</b> [NCT00685776] n=811/812 follow-up:	anacetrapib 100mg fr 18 months versus placebo	patients with coronary heart disease or at high risk for coronary heart disease	Parallel groups double-blind 20 countries
<b>REVEAL HPS-3 TIMI-55 , 2017</b> [NCT01252953] n=30624 follow-up: median 4 years	anacetrapib 100mg daily versus placebo	high risk patients already taking statins	Parallel groups double-blind
<b>REALIZE , 2015</b> [NCT01524289] n=204/102 follow-up: 52 weeks	oral anacetrapib 100 mg for 52 weeks versus placebo	patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 259 mmol/L or higher without cardiovascular disease or 181 mmol/L or higher with cardiovascular disease	Parallel groups double-blind

More details and results :

- CEPT inhibition for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q340>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

## References

### DEFINE, 2010:

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. N Engl J Med 2010 Nov 17;; [21082868] [10.1056/NEJMoa1009744](https://doi.org/10.1056/NEJMoa1009744)

### REVEAL HPS-3 TIMI-55, 2017:

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017;; [28847206]

**REALIZE, 2015:**

Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y  
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase  
3 study. Lancet 2015 Mar 2;; [25743173] [10.1016/S0140-6736\(14\)62115-2](https://doi.org/10.1016/S0140-6736(14)62115-2)

Entry terms: MK 0859, MK0859, MK-0859,